News und Analysen

Regulatory News:

Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO₂VATE, Akebia’s global phase-III cardiovascular outcomes

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2020, and provided an update on the impact of the COVID-19 pandemic.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2020, highlighting revenue growth and financial strength, clinical pipeline developments and the company’s

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.

For the first quarter of 2020, worldwide sales

Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen für Medizintechnik und Innovationen, gab heute bekannt, dass seine Bi-Flow-Kanüle für extrakorporale Membranoxygenierung (ECMO) die

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for

Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a

Premier Inc. (NASDAQ: PINC) plans to report fiscal 2020 third-quarter financial results the morning of May 5, 2020, followed by a conference call at 8 a.m. ET to discuss the results.

Conference

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2020 results on Wednesday, May 6, at approximately 22:0

ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

Chemed Corporation (NYSE:CHE) announced today that the Company will hold its 2020 Annual Meeting of Stockholders in a virtual-only format due to public health concerns relating to the coronavirus

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005949/en/

Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, is marshaling all its data and technology capabilities to provide real-time, integrated solutions that help make it easier for

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that isolation gowns surpassed N95 masks as the top personal protective equipment (PPE)

Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2020, on Tuesday, April 28, 2020, following the close of trading on the

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7^th, before the market opens. A conference call has been scheduled to

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug